A veteran of 10 startup/early development healthtech companies and CROs, Mark leads the team at Nanovery. Originally a molecular biologist, he moved into commercial roles early in his career and has experience of several ‘build to acquisition’ journeys, the most recent being Arcinova (sold to Quotient Sciences).

Mark will speak on Nanovery’s DNA nanorobot platform and the remarkable progress the company has achieved in the last 12 months, securing its first customers for the bioanalysis of nucleic acids. This development has been supported by ATD bio with consistent quality, quantity and turnaround times for oligo delivery.

On the 24th of September, ATDBio proudly hosted its inaugural Oligonucleotide Symposium at Worcester College, Oxford. The event brought together over 80 attendees from a wide range of disciplines and organisations, both academic and commercial, who were all eager to explore the latest advancements in oligonucleotides and their transformative impact on fields such as diagnostics, therapeutics, and DNA nanotechnology.

If you were unable to make it to the presentation this year and would be interested in attending future events, or if you would be interested in presenting your own work, please reach out to us – we would love to hear from you.